10.5281/zenodo.3555339
https://zenodo.org/records/3555339
oai:zenodo.org:3555339
Harding, Rachel
Rachel
Harding
0000-0002-1134-391X
Structural Genomics Consortium, University of Toronto
Hutchinson, Ashley
Ashley
Hutchinson
Structural Genomics Consortium, University of Toronto
Seitova, Alma
Alma
Seitova
Structural Genomics Consortium, University of Toronto
Arrowsmith, Cheryl
Cheryl
Arrowsmith
Structural Genomics Consortium, University of Toronto
Edwards, Aled
Aled
Edwards
Structural Genomics Consortium, University of Toronto
Large-scale purification of Q23 and Q54 HTT-HAP40 from Sf9 expression system in PBS 2019/09/16
Zenodo
2019
huntingtin
huntington's disease
Protein purification
2019-09-16
10.5281/zenodo.3555338
https://zenodo.org/communities/labscribbles
https://zenodo.org/communities/sgc-opennotebook
https://zenodo.org/communities/openlabnotebooks
Creative Commons Attribution 4.0 International
Project: Biophysical investigation of purified HTT protein samples
Experiment: Large-scale purification of Q23 and Q54 HTT-HAP40 from Sf9 expression system in PBS.
Date completed: 2019/09/16
Rationale: To purify HTT-HAP40 Q23 and Q54 in PBS to see if this reduces nucleic acid contamination.
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.